pharmaceutical investing Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05
Placement to Institutional and Sophisticated Investors, Appointment of Joint Broker,Issue of Equity & TVR